These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17310065)

  • 1. An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities.
    Kalie E; Jaitin DA; Abramovich R; Schreiber G
    J Biol Chem; 2007 Apr; 282(15):11602-11. PubMed ID: 17310065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2.
    Marijanovic Z; Ragimbeau J; van der Heyden J; Uzé G; Pellegrini S
    Biochem J; 2007 Oct; 407(1):141-51. PubMed ID: 17627610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities.
    Kalie E; Jaitin DA; Podoplelova Y; Piehler J; Schreiber G
    J Biol Chem; 2008 Nov; 283(47):32925-36. PubMed ID: 18801736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta.
    Jaitin DA; Roisman LC; Jaks E; Gavutis M; Piehler J; Van der Heyden J; Uze G; Schreiber G
    Mol Cell Biol; 2006 Mar; 26(5):1888-97. PubMed ID: 16479007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of the IFNAR1 binding site on IFNalpha2 reveals the architecture of a weak ligand-receptor binding-site.
    Roisman LC; Jaitin DA; Baker DP; Schreiber G
    J Mol Biol; 2005 Oct; 353(2):271-81. PubMed ID: 16171819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMR mapping of the IFNAR1-EC binding site on IFNalpha2 reveals allosteric changes in the IFNAR2-EC binding site.
    Akabayov SR; Biron Z; Lamken P; Piehler J; Anglister J
    Biochemistry; 2010 Feb; 49(4):687-95. PubMed ID: 20047337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2.
    Piehler J; Schreiber G
    J Mol Biol; 1999 Nov; 294(1):223-37. PubMed ID: 10556041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential receptor subunit affinities of type I interferons govern differential signal activation.
    Jaks E; Gavutis M; Uzé G; Martal J; Piehler J
    J Mol Biol; 2007 Feb; 366(2):525-39. PubMed ID: 17174979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers.
    Lamken P; Lata S; Gavutis M; Piehler J
    J Mol Biol; 2004 Jul; 341(1):303-18. PubMed ID: 15312780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFNalpha2.
    Piehler J; Schreiber G
    J Mol Biol; 1999 May; 289(1):57-67. PubMed ID: 10339405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S27 of IFNα1 Contributes to Its Low Affinity for IFNAR2 and Weak Antiviral Activity.
    Sharma N; O'Neal AJ; Gonzalez C; Wittling M; Gjinaj E; Parsons LM; Panda D; Khalenkov A; Scott D; Misra S; Rabin RL
    J Interferon Cytokine Res; 2019 May; 39(5):283-292. PubMed ID: 30920934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential use of the betaL subunit of the type I interferon (IFN) receptor determines signaling specificity for IFNalpha2 and IFNbeta.
    Domanski P; Nadeau OW; Platanias LC; Fish E; Kellum M; Pitha P; Colamonici OR
    J Biol Chem; 1998 Feb; 273(6):3144-7. PubMed ID: 9452423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. USP18 establishes the transcriptional and anti-proliferative interferon α/β differential.
    Francois-Newton V; Livingstone M; Payelle-Brogard B; Uzé G; Pellegrini S
    Biochem J; 2012 Sep; 446(3):509-16. PubMed ID: 22731491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the binding affinity of a carrier protein: a case study on the interaction between soluble ifnar2 and interferon beta.
    Peleg-Shulman T; Roisman LC; Zupkovitz G; Schreiber G
    J Biol Chem; 2004 Apr; 279(17):18046-53. PubMed ID: 14960565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted mutations in IFNα2 improve its antiviral activity against various viruses.
    Karakoese Z; Le-Trilling V-TK; Schuhenn J; Francois S; Lu M; Liu J; Trilling M; Hoffmann D; Dittmer U; Sutter K
    mBio; 2023 Dec; 14(6):e0235723. PubMed ID: 37874130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stat2 binding to the interferon-alpha receptor 2 subunit is not required for interferon-alpha signaling.
    Nguyen VP; Saleh AZ; Arch AE; Yan H; Piazza F; Kim J; Krolewski JJ
    J Biol Chem; 2002 Mar; 277(12):9713-21. PubMed ID: 11786546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor density is key to the alpha2/beta interferon differential activities.
    Moraga I; Harari D; Schreiber G; Uzé G; Pellegrini S
    Mol Cell Biol; 2009 Sep; 29(17):4778-87. PubMed ID: 19564411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variations in the unstructured C-terminal tail of interferons contribute to differential receptor binding and biological activity.
    Slutzki M; Jaitin DA; Yehezkel TB; Schreiber G
    J Mol Biol; 2006 Jul; 360(5):1019-30. PubMed ID: 16815442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Creation of interferon-alpha8 mutants with amino acid substitutions against interferon-alpha receptor-2 binding sites using phage display system and evaluation of their biologic properties.
    Yamamoto K; Taniai M; Torigoe K; Yamamoto S; Arai N; Suemoto Y; Yoshida K; Okura T; Mori T; Fujioka N; Tanimoto T; Miyata M; Ariyasu H; Ushio C; Fujii M; Ariyasu T; Ikeda M; Ohta T; Kurimoto M; Fukuda S
    J Interferon Cytokine Res; 2009 Mar; 29(3):161-70. PubMed ID: 19196068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human interferon-ϵ and interferon-κ exhibit low potency and low affinity for cell-surface IFNAR and the poxvirus antagonist B18R.
    Harris BD; Schreiter J; Chevrier M; Jordan JL; Walter MR
    J Biol Chem; 2018 Oct; 293(41):16057-16068. PubMed ID: 30171073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.